The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This randomized controlled trial investigates the effect of a single dose of glucagon-like
peptide-1 (GLP-1) receptor agonist on cerebral blood flow velocity and cortical oxygination
in humans without cerebrovascular disease. This study serves as a control for a similar study
investigating the effect in stroke patients (ref. to EGRABIS1).